Particle.news
Download on the App Store
3 ARTICLES
·
last mo.

New Analysis Suggests Ubrogepant May Ease Early Migraine Symptoms

Reanalysis of the PRODROME study indicates Ubrogepant could reduce prodromal symptoms like light sensitivity, but further trials are needed to confirm findings.

Eine Frau fasst sich an den Kopf. (Archivbild)
Das Migränemittel Ubrogepant könnte auch gegen die Vorboten-Symptome von Migräneattacken wirken. © peterschreiber.media/ iStock

Overview

  • The reanalysis of the 2023 PRODROME study suggests that Ubrogepant, when taken preemptively, may alleviate migraine prodromal symptoms such as light sensitivity, fatigue, and neck stiffness.
  • In the study, 19.5% of participants reported reduced light sensitivity two hours after taking Ubrogepant, compared to 12.5% in the placebo group.
  • Ubrogepant, a CGRP receptor antagonist approved in the United States since 2019 for acute migraine treatment, has not yet been approved in Europe.
  • Experts emphasize the need for dedicated, controlled clinical trials to substantiate Ubrogepant's potential efficacy in addressing the prodromal phase of migraines.
  • Other gepants, such as Atogepant and Rimegepant, are approved in Europe, but their effectiveness in treating prodromal symptoms remains unexplored.